A carregar...
Elexacaftor–Tezacaftor–Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype
The new CFTR modulator combination, elexacaftor/tezacaftor/ivacaftor (Trikafta) was approved by the FDA in October 2019 for treatment of Cystic Fibrosis in patients 6 years of age or older who have at least one F508del mutation in one allele and a minimal-function or another F508del mutation in the...
Na minha lista:
| Publicado no: | Antibiotics (Basel) |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8300667/ https://ncbi.nlm.nih.gov/pubmed/34356748 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/antibiotics10070828 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|